Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for resistant ovarian cancer

NCT ID NCT03776812

Completed Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the cancer from growing longer than chemotherapy alone. Participants received either the combination or chemotherapy only, and the study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma ovarian carcinosarcoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CANCER RECURRENT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

  • Site Reference ID/Investigator #001

    Chicago, Illinois, 60637, United States

  • Site Reference ID/Investigator #004

    Birmingham, Alabama, 35249, United States

  • Site Reference ID/Investigator #032

    Denver, Colorado, 80045, United States

  • Site Reference ID/Investigator #038

    Scottsdale, Arizona, 85258, United States

  • Site Reference ID/Investigator #051

    New York, New York, 10065, United States

  • Site Reference ID/Investigator #096

    Montreal, Quebec, H2X 0A9, Canada

  • Site Reference ID/Investigator #106

    Boston, Massachusetts, 02215, United States

  • Site Reference ID/Investigator #108

    Leuven, 3000, Belgium

  • Site Reference ID/Investigator #109

    Brussels, 1200, Belgium

  • Site Reference ID/Investigator #112

    Naples, 80131, Italy

  • Site Reference ID/Investigator #113

    Valencia, 46009, Spain

  • Site Reference ID/Investigator #114

    Madrid, 28034, Spain

  • Site Reference ID/Investigator #115

    Barcelona, 08035, Spain

  • Site Reference ID/Investigator #116

    Madrid, 28034, Spain

  • Site Reference ID/Investigator #117

    Toronto, Ontario, M4N 3M5, Canada

  • Site Reference ID/Investigator #119

    Edegem, 2650, Belgium

  • Site Reference ID/Investigator #121

    Milwaukee, Wisconsin, 53226, United States

  • Site Reference ID/Investigator #122

    Milan, 20141, Italy

  • Site Reference ID/Investigator #124

    Roma, 00168, Italy

  • Site Reference ID/Investigator #127

    Pittsburgh, Pennsylvania, 15213, United States

  • Site Reference ID/Investigator #128

    Boston, Massachusetts, 02215, United States

  • Site Reference ID/Investigator #135

    Charlottesville, Virginia, 22908, United States

  • Site Reference ID/Investigator #169

    New York, New York, 10065, United States

  • Site Reference ID/Investigator #170

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.